推荐产品
质量水平
方案
95%
表单
powder with small lumps
反应适用性
reaction type: solution phase peptide synthesis
mp
275-280 °C (dec.) (lit.)
应用
detection
peptide synthesis
SMILES字符串
Nc1ccc(O)c(c1)C(O)=O
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
基因信息
human ... ALOX5(240) , PPARG(5468) , PTGS1(5742) , PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
相关类别
应用
5-氨基水杨酸是适用于ELISA分析的过氧化物酶底物。这一底物产生可溶性的棕色终产物，可在450nm处通过分光光度法读取。使用3 N NaOH可终止反应并在550 nm处读取结果。
警示用语：
Warning
危险分类
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
靶器官
Respiratory system
储存分类代码
13 - Non Combustible Solids
WGK
WGK 2
闪点(°F)
No data available
闪点(°C)
No data available
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
Mirjana Rajilić-Stojanović et al.
Inflammatory bowel diseases, 19(3), 481-488 (2013-02-07)
Presence of intestinal microbes is a prerequisite for the development of ulcerative colitis (UC), although deviation of the normal intestinal microbiota composition, dysbiosis, is presumably implicated in the etiology of UC. The fecal microbiota of 30 UC samples obtained from
Christian P Selinger et al.
Inflammatory bowel diseases, 19(10), 2199-2206 (2013-08-01)
Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets
Urpo Nieminen et al.
International journal of cancer, 134(1), 189-196 (2013-06-26)
Patients with long-standing inflammatory bowel disease (IBD) have an increased risk for colorectal carcinoma (CRC). Earlier studies suggest that the severity of inflammation is an independent risk factor for CRC in ulcerative colitis (UC). We investigated the role of histological
W Kruis et al.
Alimentary pharmacology & therapeutics, 37(7), 680-690 (2013-02-19)
Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (DD) is sparse. To investigate mesalazine (Salofalk granules) in this setting. In a double-blind, placebo-controlled, multicentre, 6-week trial, patients were randomised to mesalazine 1000 mg three times daily or placebo.
B Flourié et al.
Alimentary pharmacology & therapeutics, 37(8), 767-775 (2013-03-05)
Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. To compare the efficacy and safety of once- (OD) vs. twice- (BD) daily prolonged-release mesalazine (Pentasa, Ferring, Saint-Prex, Switzerland) for active mild-to-moderate UC in a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门